Many of you that follow these things closely will have already seen this news yesterday - but since it means a little something different for us, I wanted to share. Intermune (the company that makes the drug pirfenidone, brand name Esbriet) announced the results of their ASCEND trial yesterday and they were good! This means that the company will be moving forward to try to get FDA approval for the drug to treat IPF (idiopathic pulmonary fibrosis). So, for those who haven't followed this saga or for the new folks, here's a little background on all this and the tie-in for HPS. Back in the late 90s the NIH conducted a small phase II trial of this drug to treat the PF of HPS. The results were promising. It is NOT a cure, but did slow down the progression of the lung disease. We were ready to do our phase III trial, but the drug was sold to another company and our trials were put on hold for several years (very frustrating). Finally, in 2006 we were able to start our phase III trial
Stories from the battle to cure Hermansky-Pudlak Syndrome, and other observations about every day life